theblindsquirrel

Author Bio

theblindsquirrel
These past 65 years have seen me wander down many and varied roads, the most significant of which was the 20 years I spent working as a Registered Financial Consultant with four of Wall Streets largest and most respected firms: Merrill Lynch (1984 – 1991), UBS PaineWebber (1991 – 1998), Prudential Securities (1998 – 2000), and Edward Jones & Co (2000 – 2003). I worked with hundreds of clients, helped manage tens of millions of dollars of portfolio assets, and went through some of the best of times in the market – the Great Bull of ’82 – ’99 for example, and the absolute worst – the Crash of October 1987. I’ve seen great success, been brought low by unfortunate circumstance, and found a way out of the situations with a boatload of knowledge that I am pleased to share when appropriate. That’s what I plan to deliver to you over time so that you may learn a thing or two that will probably never be spoken of elsewhere. I hope you enjoy and benefit from it.Jim Skelton is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

Market Acrophobia – The Fear of Falling

[Ed. note: Today we have another article from Jim Skelton, the Blind Squirrel, who writes to share what he learned about investing in his many years in the trenches as a financial advisor. He has agreed to our trading restrictions, the opinions he expresses are his own, and we haven’t reviewed, approved or screened his […]

Just For the Record

[Ed. note: Today we have another article from Jim Skelton, the Blind Squirrel, who is sharing his experiences as a financial advisor with us. He has agreed to our trading restrictions, the opinions he expresses are his own, and we haven’t reviewed, approved or screened his ideas. His previous articles can be seen here.]  Hello, fellow […]

Paradise Gained, Paradise Lost – Part Two

[Ed. note: Here is the next exciting installment from Jim Skelton, the Blind Squirrel, who is sharing his experiences as a financial advisor with us. As with all of our contributors, the opinions he expresses are his own, and we haven’t reviewed, approved or screened his ideas. His previous articles can be seen here.]  Greetings […]

Paradise Gained, Paradise Lost, Part One

[Ed. note: Here is our first article from Jim Skelton, the Blind Squirrel, who is writing about his experiences as a financial advisor. As with all of our contributors, the opinions he expresses are his own, and we haven’t reviewed, approved or screened his ideas.] Hello and welcome to all you citizens of the Gumshoe […]

Access .. DENIED!

This is more of a question I’d pose to you other Irregulars who, like me, enjoy and appreciate Myrons commentaries and suggestions for investment. Here’s the question: Have any of you tried to buy one on Myrons picks that trades on a foreign exchange and been denied access to that platform? Last week this happened […]

Recent Author Comments

On Friday File: Lessons for a Volatile Week (plus two buys)
Travis, you make many good points in your discussion of managing risk and managing your mind as we go through this correction. Thank you for that thoughtful reminder that markets will always have periods that test our resolve. In keeping with these strate[...]
On Biotech Discussion... continued
First, may I offer my sincere thanks for the the warm welcome I have received from many of you upon my return from hibernation. I'll work to earn that welcome. And I would like to add this directed to those who replied in some manner to my statements regar[...]
On Biotech Discussion... continued
Hello fellow Gummies! It's been quite a while since I actively joined in to any discussion on the threads here. Some of you who have been a member since early 2014 or so may remember me as "The Blind Squirrel". I first appeared on these pages as author an[...]
On The Rest of the 12 Biotechs of Christmas
$No Ticker re Motif investing. Having spent 20+ years as an Investment Adviser, I ran into situations similar to what you will encounter with Motif investing during the late 1990's in the .com and Telecom meltdown. Many clients owned either mutual funds or[...]
On Microblog: Discussion re $ARTH
An uplisting requires a Company to meet specific criteria before it can happen. Being "uplisted" to, say, NASDAQ, does have certain benefits: greater visibility by the general public, possible analyst coverage, the ability for some new types of investors o[...]
On Microblog: Discussion re $ARTH
Alan: System test. advise good / no good to go. J[...]
On Microblog: Discussion re $ARTH
I'm going to come clean here about something I did yesterday (Wed) that I felt the total fool for by day end. I had watched as my position dropped from Fridays close of being up ~ 75% to being up ~ 30% . And price was tumbling. I decided to live by the old[...]
On Microblog: Discussion re $ARTH
Dropping on FEAR period. And trading. Damn the day this "Fib" stuff first appeared ... IMO, of course.[...]
On Microblog: Discussion re $ARTH
Alan - re your comment about being nimble to buy shares on dips created by basement-dwelling traders. Remember this old rhyme before trying .. "Jack be nimble, Jack be quick. Jack jumped over the candlestick. Jack got his ass burned well and proper in the [...]
On Microblog: Discussion re $ARTH
Sharon: You provide as concise a summary of what I believe would be the primary concerns of most of us that bought into $ARTH back at the start of all this as I have seen. The primary idea was that they had a clear and open field to research, develop, tria[...]
On "For Less than $8 a Share, You Can Buy the Best Tech Stock"
Off topic here, but wanted to commiserate with you re that lost article you are having to re-write. Been there, done that (haven't we all?), and it makes me want to scream (actually, I have sat and actually screamed at the laptop when it happened), throw u[...]
On The Second Coming of TransEnterix?
By any chance did you find a way to connect to the Mayor of Gummiedom, Alan H., while in Merry Olde England? I sure wish he and I could meet up and share a pint - perhaps a gallon - of good British Ale some day and swap lies about financial successes.[...]
On The Second Coming of TransEnterix?
As always, beautiful work from a beautiful mind. I am constantly in search of medical device companies in which to position a few dollars, and TRXC would seem to fit the criteria of a potentially very profitable company with a near-market-ready device that[...]
On Microblog: BIOTECH IN A Dr. KSS-LESS WORLD
NUZZLES: THAT'S WHAT SHE SAID. :0)[...]
On Microblog: BIOTECH IN A Dr. KSS-LESS WORLD
Looking at current price of $PARN and price action of past 3 days made me choke a bit with suggestion of it being a "great idea". If, and only if, they get final approval for introduction of their drug into US Vets offices will it be worth a Tinkers damn.[...]
On Revealing "The Top 10 Stocks For 2015" from Street Authority
For those who may be wondering how this little "top 10" portfolio has done since Jan 2, here's a quick take. I looked up the opening price of each of the stocks on Jan 2 and assumed a buy of one share each. That would have cost $619.30 before commissions.[...]
On Revealing "The Top 10 Stocks For 2015" from Street Authority
Thanks, Travis. I'm improving. Actually have an idea for two new articles, one of which involves a "top 10" list I've been using since mid-December '14 for readers to ponder. Maybe, just maybe, you'll get that by months end. Will wonders never cease![...]
On Revealing "The Top 10 Stocks For 2015" from Street Authority
In the "Quick Take" box I see the symbol ($MO) listed for the recommended holding of Phillip Morris. But In the body of the article I see the recommendation is actually for symbol ($PM) which is for Phillip Morris International. Symbol ($MO) is the US divi[...]
On Microblog: The Gain from Pain Mainly Explained
Dr. KSS; Congratulations on what I see as your finest work yet! Opens with some action/adventure thriller to get us involved, moves onto hard science in the discussion of pain and the intricate nature of it, and finished with a terrific discussion (as opp[...]
On Microblog: Special Update on Cellceutix
Jon: If I read correctly, these 16 tranches will be rolled out over the coming 2 years. Therefore, your statement of "push down the price once a year for the next 16 tranches" is misleading. The implication is that this stock could hit the market every ye[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.